INCB054707
Showing 1 - 13 of 13
Hidradenitis Suppurativa (HS) Trial (Povorcitinib, Placebo)
Not yet recruiting
- Hidradenitis Suppurativa (HS)
- Povorcitinib
- Placebo
- (no location specified)
Nov 10, 2022
Renal Insufficiency, Kidney Diseases Trial in Orlando, Munich (INCB054707)
Recruiting
- Renal Insufficiency
- Kidney Diseases
- INCB054707
-
Orlando, Florida
- +1 more
Jan 31, 2023
Healthy Participants Trial in Fukuoka (INCB054707, Placebo)
Completed
- Healthy Participants
- INCB054707
- Placebo
-
Fukuoka, JapanSouseikai Fukuoka Mirai Hospital
Sep 14, 2022
Renal Insufficiency, Kidney Diseases Trial in Orlando (INCB054707)
Not yet recruiting
- Renal Insufficiency
- Kidney Diseases
- INCB054707
-
Orlando, FloridaOrlando Clinical Research
Nov 15, 2022
Hidradenitis Suppurativa Trial in United States (INCB054707)
Completed
- Hidradenitis Suppurativa
- INCB054707
-
Los Angeles, California
- +3 more
Sep 14, 2022
Renal Insufficiency, Kidney Diseases Trial in Germany, United States (INCB054707)
Recruiting
- Renal Insufficiency
- Kidney Diseases
- INCB054707
-
Tustin, California
- +3 more
Nov 15, 2022
Hidradenitis Suppurativa Trial in Canada, Denmark, Germany (INCB054707, Placebo)
Completed
- Hidradenitis Suppurativa
- INCB054707
- Placebo
-
Winnipeg, Manitoba, Canada
- +12 more
Feb 25, 2022
NonSegmental Vitiligo Trial in Canada, United States (INCB054707, Placebo)
Active, not recruiting
- NonSegmental Vitiligo
- INCB054707
- Placebo
-
Hoover, Alabama
- +30 more
Nov 14, 2022
Hidradenitis Suppurativa (HS) Trial in Worldwide (Povorcitinib, Placebo)
Recruiting
- Hidradenitis Suppurativa (HS)
- Povorcitinib
- Placebo
-
Phoenix, Arizona
- +44 more
Jan 12, 2023
Prurigo Nodularis Trial in Worldwide (INCB054707, Placebo)
Recruiting
- Prurigo Nodularis
- INCB054707
- Placebo
-
Phoenix, Arizona
- +48 more
Dec 1, 2022
Hidradenitis Suppurativa, Acne Inversa Trial in Worldwide (INCB054707, Placebo)
Active, not recruiting
- Hidradenitis Suppurativa
- Acne Inversa
- INCB054707
- Placebo
-
Hoover, Alabama
- +39 more
Apr 29, 2022